• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit/AskCarlat AI
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Keywords » QTc prolongation

Items Tagged with 'QTc prolongation'

ARTICLES

Clinical Update

Update on Psychocardiology for Older Adults

October 1, 2026
Roy Williams, MD, MPH
From The Carlat Geriatric Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Roy Williams, MD, MPH. Transplant psychiatry and consultation-liaison psychiatry, Baylor College of Medicine, Houston, TX.

Dr. Williams has no financial relationships with companies related to this material.

Is it the heart or the mind—and which psychotropic is safe to prescribe? This update reviews QTc risk, orthostasis, and metabolic effects across antidepressants and antipsychotics in cardiac patients.


Read More
Research Update

Escitalopram Doesn't Replace Citalopram for Agitation in Alzheimer's Disease

October 1, 2026
Carlat Staff
From The Carlat Geriatric Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Compiled by Carlat Editorial Staff and Reviewed by the Editor-in-Chief and the Editorial Board.

Staff members have no financial relationships with companies related to this material.

Citalopram works for agitation in Alzheimer's disease but comes with QTc concerns and strict dosing limits. Escitalopram, its purer enantiomer, seemed like an obvious fix. Is it as effective for agitation?


Read More
What You Need to Know About Gepirone (Exxua) _ Benefits, Side Effects, and Review of Trials_Thumb.jpg

What You Need to Know About Gepirone (Exxua) | Benefits, Side Effects, and Review of Trials

September 27, 2024
Chris Aiken, MD. and Greg Malzberg, MD
In this video, Dr. Chris Aiken, Editor-in-Chief of The Carlat Psychiatry Report, provides a comprehensive review of Gepirone, also known as Exxua, a newly FDA-approved antidepressant for major depressive disorder in adults. Gepirone is unique due to its classification as an azipirone, a class of medications that work as serotonin 5-HT1A receptor agonists. 
Read More
canstockphoto60629555.jpg

QT Intervals in Psychiatric Practice

June 19, 2023
Victoria Hendrick, MD. and Prabhjot Gill

Several psychiatric medications prolong the QTc interval and place patients at risk of the dreaded torsade de pointes. Some patients are particularly vulnerable to QTc prolongation: the elderly, patients with heart disease and electrolyte imbalances, and patients taking certain medications, like thioridazine and ziprasidone. In this podcast, we provide a step-by-step guide so that you can keep your patients safe from this cardiovascular side effect.


Read More
Try The New AskCarlat AI

Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

Available In The Carlat Toolkit
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • CAM1e_3DCover_Spiral_sm.png

    Complementary and Alternative Medicine in Psychiatry: A Fact Book (2026) -

    Fact sheets for 67 treatments that fall outside conventional psychopharmacology.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2205347851.jpg
    General Psychiatry

    Balancing Focus and Cardiovascular Risk with ADHD Treatment

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.